ClinicalTrials.gg
Active, not recruitingNCT06087835Updated Oct 13, 2026

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

A Phase 3 interventional study of Zibotentan/Dapagliflozin and Dapagliflozin in Chronic Kidney Disease With High Proteinuria, sponsored by AstraZeneca. Active, not recruiting at 296 sites in 30 countries. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,835
Allocation
Randomized
Ages
18 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Kidney Diseases by AstraZeneca — none open to participants now, 3 under way, 2 of them phase 3. Kidney Diseases · AstraZeneca.

Started
2023
with 1 other
Phase 3
4 of 11
none open now
Registered
9th of 11
by date

Among the 11 studies in Kidney Diseases by AstraZeneca, this one is one of 2 that started in 2023, is one of 4 in phase 3, and was the 9th registered.

Kidney Diseases

970 studies on the registry are indexed under Kidney Diseases; 185 are open to participants now.

Browse Kidney Diseases studies →

Open to participants now

None of the 11 studies in Kidney Diseases by AstraZeneca is open now. The open studies under Kidney Diseases, anywhere →

Who these studies take

Of the 131 Kidney Diseases studies recruiting now, 77 (59%) set no upper age limit and 34 (26%) stop at 75 or younger; 27 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 95 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Kidney Diseases by AstraZeneca as a file.
02

Study summary

This is a Phase III, randomised, multicentre, double-blinded study to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney disease (CKD) and high proteinuria

03

Conditions studied

  • Chronic Kidney Disease With High Proteinuria

Browse trials for

Keywords

  • Zibotentan
  • Nephrology
  • Dapagliflozin
  • Sodium-glucose co-transporter 2
  • sodium-glucose co-transporter 2 inhibitor
  • Kidney diseases
  • Endothelin antagonist
  • High Proteinuria
04

Who can participate

Ages eligible
18 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be ≥ 18 years of age and of legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the .
  2. Diagnosis of CKD, defined as ≥ 20 and \< 90 mL/min/1.73 m2 and UACR > 700 mg/g (> 79 mg/mmol) or UPCR > 1000 mg/g (> 113 mg/mmoL).
  3. All female participants must have a negative serum pregnancy test result at screening.
  4. Female participants must be either

    • not of or
    • women of child bearing potential (WOCBP) using at least one highly effective method for at least 3 months prior to first dose of study intervention
  5. Capable of giving signed informed consent
  6. Provision of signed informed consent prior to any study specific procedure.
  7. Provision of electronic informed consent prior to completion of the optional Study Participant Feedback Questionnaire (SPFQ).
  8. Provision of signed and dated written Optional Genomics Initiative Research Information and Consent Form prior to collection of samples for optional genomics imitative research that supports the Genomic Initiative.
  9. Receiving RAASi therapy (ACEi or ARB), and for the patient maximum tolerated labelled daily dose, that has been stable for at least 4 weeks.

Exclusion criteria

Exclusion Criteria:

  1. Participants with class III or class IV Congestive HF at the time of enrolment.
  2. Participants hospitalised for HF during the last 6 month prior to screening.
  3. Evidence of rales or jugular venous distention on physical examination.
  4. Participants with type 1 diabetes mellitus.
  5. History of any life-threatening ventricular dysrhythmia (continuous or paroxysmal).
  6. Blood pressure above 160 mmHg systolic.
  7. Blood pressure below 90 mmHg systolic.
  8. Participants hospitalised for heart disease or cardiac procedures or for COVID-19 during the last 3 months prior to screening.
  9. History of solid organ transplantation or bone marrow transplant.
  10. History or ongoing allergy/, as judged by the Investigator, to SGLT2i therapy (eg, dapagliflozin, canagliflozin, empagliflozin or other SGLT2 inhibitors) or Endothelin Receptor Antagonists (eg, ambrisentan, atrasentan, bosentan, or other).
  11. Any condition with a of less than 2 years based on investigator´s clinical judgment.
  12. within the past 5 years. Exceptions to this criterion include non-melanoma skin cancer and curatively treated cervical carcinoma in situ.
  13. Significant liver disease as judged by the investigator or severe hepatic impairment with or ALT > 3 × ; or total > 2 × ULN at time of screening. An isolated increase in bilirubin in participants with known Gilbert's syndrome is not a reason for exclusion.
  14. Known blood-borne diseases.
  15. , unstable, or uncontrolled medical condition as assessed by the Investigator.
  16. Participants on renal replacement therapy or previous kidney transplant.
  17. Known history of drug or alcohol abuse within 12 months of screening.
  18. Participants on treatment with strong or moderate inducer.
  19. Participants on systemic therapy other than stable maintenance therapy defined as prednisone 10 mg/day (or equivalent) or less, aziothioprine 100 mg/day or less; MMF 1000 mg/day or less for at least 3 months prior to Visit 1. Inhaled, nasal or dermatological are also allowed.
  20. Participants treated or expecting to be treated with tolvaptan, any other ERAs, or budesonide (where used to treat IBD or IgAN).
  21. Participation in another clinical study with a study intervention administered in the last 3 months.
  22. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  23. Inability of the participant, in the opinion of the investigator, to understand and/or comply with IMP, procedures and/or follow-up OR any conditions that, in the opinion of the investigator, may render the participant unable to complete the study.
  24. Previous randomisation in the present study.
  25. Women who are pregnant, breast-feeding, or women with intent of getting pregnant.
  26. Women who are not willing to use adequate or cannot, in the opinion of the investigator, understand and/or comply with the study procedures.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,835 participants (actual)

Study arms

  • Experimental
    Zibotentan/Dapagliflozin dose A or Zibotentan/Dapagliflozin dose B

    Drug dose (dose A or B) are determined based on eGFR values. Participants will receive daily oral dose of zibotentan/dapagliflozin in fixed dose combination.

    Drug: Zibotentan/Dapagliflozin

  • Active comparator
    Dapagliflozin alone

    Participants will receive daily oral dose of dapagliflozin.

    Drug: Dapagliflozin

Interventions

  • DrugZibotentan/Dapagliflozin

    Drug pages: ZD4054 · Dapagliflozin

    Participants will receive zibotentan/dapagliflozin in fixed-dose combination as per the arms they are randomized to

  • Participants will receive dapagliflozin as per the arms they are randomized to

06

What researchers measure

Primary outcomes

  1. Change in eGFR from baseline

    To determine whether zibotentan and dapagliflozin in fixed dose combination is superior to dapagliflozin alone to slow decline in kidney function

    Time frame: At month 24

Secondary outcomes

  1. Change in Urine Albumin to Creatinine Ratio (UACR) from baseline

    To determine whether zibotentan and dapagliflozin in fixed dose combination is superior to dapagliflozin alone in reducing albuminuria

    Time frame: at Month 9

  2. Time to the first occurrence of any of the components of the renal composite endpoint of 40% sustained decline in eGFR or ESKD or renal death

    To determine whether zibotentan and dapagliflozin in fixed dose combination is superior to dapagliflozin alone in reducing the incidence of the renal composite endpoint of 40% sustained decline in eGFR or ESKD or renal death

    Time frame: Through study completion, approximately 38 months

  3. Change in Urine Protein to Creatinine Ratio (UPCR) from baseline

    To determine whether zibotentan and dapagliflozin in FDC is superior to dapagliflozin alone in reducing proteinuria in the biopsy-confirmed IgAN subgroup

    Time frame: at Month 9

07

Study locations

296 sites
  • Research Site
    Huntsville, Alabama 35805, United States
  • Research Site
    Sun City West, Arizona 85375, United States
  • Research Site
    Bakersfield, California 93309, United States
  • Research Site
    Huntington Park, California 90255, United States
  • Research Site
    Los Alamitos, California 90720, United States
  • Research Site
    Los Angeles, California 90010, United States
  • Research Site
    Northridge, California 91324, United States
  • Research Site
    Oxnard, California 93036, United States
  • Research Site
    San Carlos, California 94070, United States
  • Research Site
    San Dimas, California 91773, United States
  • Research Site
    Tarzana, California 91356, United States
  • Research Site
    Victorville, California 92392, United States
  • Research Site
    Arvada, Colorado 80002, United States
  • Research Site
    Denver, Colorado 80230, United States
  • Research Site
    Boynton Beach, Florida 33435, United States
  • Research Site
    Hialeah, Florida 33016, United States
  • Research Site
    Hollywood, Florida 33024, United States
  • Research Site
    Jacksonville, Florida 32204, United States
  • Research Site
    Jensen Beach, Florida 34957, United States
  • Research Site
    Miami, Florida 33126, United States
  • Research Site
    Miami, Florida 33165, United States
  • Research Site
    Orlando, Florida 32806, United States
  • Research Site
    Fayetteville, Georgia 30214, United States
  • Research Site
    Champaign, Illinois 61822, United States
  • Research Site
    Chicago, Illinois 60616, United States
  • Research Site
    Hinsdale, Illinois 60521, United States
  • Research Site
    Island Lake, Illinois 60042, United States
  • Research Site
    Skokie, Illinois 60077, United States
  • Research Site
    Bowling Green, Kentucky 42101, United States
  • Research Site
    Shreveport, Louisiana 71101, United States
  • Research Site
    Silver Spring, Maryland 20901, United States
  • Research Site
    Flint, Michigan 48504, United States
  • Research Site
    Flint, Michigan 48532, United States
  • Research Site
    Troy, Michigan 48098, United States
  • Research Site
    City of Saint Peters, Missouri 63376, United States
  • Research Site
    Albany, New York 12205, United States
  • Research Site
    Middletown, New York 10940, United States
  • Research Site
    Orchard Park, New York 14127, United States
  • Research Site
    Greenville, North Carolina 27834, United States
  • Research Site
    Jacksonville, North Carolina 28546, United States
  • Research Site
    Kinston, North Carolina 28504, United States
  • Research Site
    New Bern, North Carolina 28562, United States
  • Research Site
    Statesville, North Carolina 28625, United States
  • Research Site
    Wilmington, North Carolina 28401, United States
  • Research Site
    Wilmington, North Carolina 28412, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Maumee, Ohio 43537, United States
  • Research Site
    Pottstown, Pennsylvania 19464, United States
  • Research Site
    East Providence, Rhode Island 02915, United States
  • Research Site
    Kingsport, Tennessee 37660, United States
  • Research Site
    Arlington, Texas 76015, United States
  • Research Site
    Austin, Texas 78726, United States
  • Research Site
    Houston, Texas 77004, United States
  • Research Site
    Houston, Texas 77099, United States
  • Research Site
    Pearland, Texas 77584, United States
  • Research Site
    San Antonio, Texas 78204, United States
  • Research Site
    San Antonio, Texas 78207, United States
  • Research Site
    San Antonio, Texas 78212, United States
  • Research Site
    Sugar Land, Texas 77478, United States
  • Research Site
    South Salt Lake, Utah 84115, United States
  • Research Site
    Alexandria, Virginia 22311, United States
  • Research Site
    Newport News, Virginia 23606, United States
  • Research Site
    Mukilteo, Washington 98275, United States
  • Research Site
    Spokane, Washington 99204, United States
  • Research Site
    Ciudad de Buenos Aires, 1280, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1425AGC, Argentina
  • Research Site
    Mar del Plata, 7600, Argentina
  • Research Site
    Mar del Plata, B7600, Argentina
  • Research Site
    Santa Fe, S3000, Argentina
  • Research Site
    Gosford, 2250, Australia
  • Research Site
    Meadowbrook, 4131, Australia
  • Research Site
    Perth, 6000, Australia
  • Research Site
    Reservoir, 3021, Australia
  • Research Site
    Reservoir, 3073, Australia
  • Research Site
    Southport, 4222, Australia
  • Research Site
    Feldkirch, 6800, Austria
  • Research Site
    Vienna, 1130, Austria
  • Research Site
    Belém, 66073-005, Brazil
  • Research Site
    Botucatu, 18618-687, Brazil
  • Research Site
    Joinville, 89227-680, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 01228-200, Brazil
  • Research Site
    São Paulo, 04012-909, Brazil
  • Research Site
    São Paulo, 04038-031, Brazil
  • Research Site
    Dobrich, 9300, Bulgaria
  • Research Site
    Pleven, 5800, Bulgaria
  • Research Site
    Plovdiv, 4000, Bulgaria
  • Research Site
    Plovdiv, 4001, Bulgaria
  • Research Site
    Sofia, 1680, Bulgaria
  • Research Site
    Stara Zagora, 6000, Bulgaria
  • Research Site
    London, Ontario N6A 5A5, Canada
  • Research Site
    Waterloo, Ontario N2T 0C1, Canada
  • Research Site
    Greenfield Park, Quebec J4V 2H1, Canada
  • Research Site
    Montreal, Quebec H4J 1C5, Canada
  • Research Site
    Baotou, 014010, China
  • Research Site
    Beijing, 100029, China
  • Research Site
    Beijing, 102218, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610000, China
  • Research Site
    Chengdu, 610072, China

Showing the first 100 of 296 sites across 30 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Muhammad Daniyal S, Ajaz H, Riaz M, Murad Khatoon N, Aftab Z, Tauqir Gondal H, Gul I, Sarwar M, Batool F, Fahim SL, Noor A, Khalid A, Ashraf DA, Jabarkhil R. Combination therapy with mineralocorticoid receptor antagonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in chronic kidney disease: an updated meta-analysis of randomized controlled trials. BMC Nephrol. 2025 Dec 22;27(1):69. doi: 10.1186/s12882-025-04710-2. PubMed 41430169 ↗
  • Smeijer JD, Wasehuus VS, Dhaun N, Gorriz JL, Soler MJ, Astrand M, Mercier AK, Greasley PJ, Ambery P, Heerspink HJL. Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD. J Am Soc Nephrol. 2024 Oct 1;35(10):1381-1390. doi: 10.1681/ASN.0000000000000436. Epub 2024 Jul 12. PubMed 39352861 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Feb 2027, 39 months after the start.

Of 45 phase 3 interventional studies under Kidney Diseases, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 69. This study's planned 39 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2023
First posted
Oct 18, 2023
StartActual
Nov 7, 2023
Primary completionEst.
Feb 18, 2027
CompletionEst.
Feb 18, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06087835
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 18, 2023
Start date
Nov 7, 2023
Primary completion
Feb 18, 2027 (estimated)
Completion
Feb 18, 2027 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: ZD4054 · Dapagliflozin

Start the discussion